Anti-CTLA-4 (Ipilimumab), Humanized Antibody

Datasheet
Specifications
Clonality: Monoclonal
Host: CHO cells
Applications: In vivo studies,Cell proliferation assay
Additional Information
Synonyms: MDX-010, BMS-734016, CTLA-4, CTLA 4, CTLA4, Yervoy
UniProt ID: DB06186

Immunogen

Ipilimumab

Application

Cell proliferation assay, In vivo studies

Background

Iplimumab is a fully humanized IgG1 monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA-4). By binding to CTLA-4, it releases the inhibitory action on cytotoxic T-lymphocytes and thus results in destruction of cancer cells. Developed by Bristol-Myers Squibb and Medarex, Iplimumab (Yervoy) was approved by FDA in 2011 to treat metastatic melanoma, metastatic colorectal cancer, and hepatocellular carcinoma. Combination therapy with Nivolumab has been recommended for advanced renal cell carcinoma

  • Catalog Number
    A2110-100-BV
  • Supplier
    BioVision
  • Size
  • Shipping
    Blue Ice
  • Price
  • 555,00 €
Add to Cart
you need any help?

Please contact:

Dr. Monika Haas

Tel. +49 (0) 6221 71415 16 info@biocat.com